Product image of Lenalidomide Grindeks (Lenalidomide) supplied by GNH India

Lenalidomide Grindeks

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Grindeks (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH India supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Manufacturer / TM Owner

Grindeks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies and related disorders, acting on abnormal plasma cells and dysplastic bone‑marrow clones.

  • Multiple Myeloma: improves progression‑free survival and overall response in adult patients.
  • Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality.
  • Mantle Cell Lymphoma: contributes to disease control when used in combination therapy for adult patients.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant cell growth and restore immune surveillance.

Side Effects

Lenalidomide may cause a range of adverse reactions, from mild to severe. Monitoring and supportive care are essential during therapy.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Thrombocytopenia: low platelet count leading to easy bruising.
  • Diarrhea: loose stools that may require hydration.
  • Constipation: difficulty passing stool.
  • Rash: mild skin irritation or erythema.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound immune suppression.
  • Serious infections: opportunistic or bacterial infections.
  • Secondary malignancies: emergence of new cancers.
  • Liver toxicity: elevated transaminases or hepatic failure.

Precautions & Warnings

Before initiating Lenalidomide, clinicians should assess patient-specific risk factors and implement appropriate monitoring.

  • Pregnancy: contraindicated; teratogenic risk requires effective contraception.
  • Thrombosis risk: evaluate history and consider prophylactic anticoagulation.
  • Hematologic monitoring: perform regular complete blood counts.
  • Renal impairment: adjust dose based on renal function.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Lenalidomide interacts with several drug classes; awareness helps prevent reduced efficacy or heightened toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly lower lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding.
  • Live vaccines: heightened risk of infection due to immunosuppression.
  • Immunosuppressants (e.g., cyclosporine): may amplify hematologic toxicity.

Moderate Interactions (Monitor Closely)

  • Antibiotics such as fluoroquinolones: may exacerbate myelosuppression.
  • Antifungals like ketoconazole: can raise plasma concentrations.
  • NSAIDs: potential additive renal stress.
  • Vaccines (non‑live): may have reduced efficacy, monitor immune response.

Frequently Asked Questions

Lenalidomide Grindeks is indicated for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes that have a del(5q) cytogenetic abnormality, and mantle cell lymphoma, typically as part of combination therapy regimens prescribed by a qualified oncologist.

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its activity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that suppress malignant cell growth and enhance immune surveillance.

The specific dose of Lenalidomide Grindeks is determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug class, offering a distinct mechanism of action compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens to improve response rates and progression‑free survival, providing an oral alternative to injectable therapies.

Lenalidomide Grindeks should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Lenalidomide Grindeks is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

The most serious risks include severe neutropenia, thrombocytopenia, venous thromboembolism, serious infections, secondary malignancies, and potential teratogenic effects. Patients should be monitored closely for signs of infection, bleeding, or clot formation, and appropriate preventive measures should be taken.

Lenalidomide Grindeks should not be used by individuals who are pregnant, have uncontrolled infections, have a known hypersensitivity to lenalidomide or any excipients, or have severe renal impairment without dose adjustment. Contraindications are determined by the treating physician based on the patient’s medical history.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT